Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | DRD1 | P21728 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6845140 | 1.00 | CHRNA7 (0.57) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL23207625 | 0.89 | CHRNA7 (0.50) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL10238796 | 0.85 | CHRNA7 (0.45) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL27894710 | 0.79 | CHRNA7 (0.55) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL6845118 | 0.79 | CHRNA7 (0.55) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL29649333 | 0.79 | CHRNA7 (0.55) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| Hydrochloric Acid SCHEMBL12983298 | 0.78 | CHRNA7 (0.54) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| Hydrochloric Acid SCHEMBL12983296 | 0.78 | CHRNA7 (0.54) | CHRNA7CHRNB2CHRNB4CHRNA4CHRNA2 | |
| SCHEMBL16692272 | 0.74 | CHRNA7 (0.40) | CHRNA7CHRNB2CHRNA4UHRF1 | |
| SCHEMBL14525626 | 0.72 | CHRNA7 (0.44) | CHRNA7UHRF1CYP1A2CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062070-B2 | Inhibitors of the renal outer medullary potassium channel | MERCK SHARP & DOHME CORP. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | MERCK SHARP & DOHME LLC | 2014-07-24 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-8501804-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-08-06 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | CHRNA7 3011/4885CHRNB2 4215/4885CHRNB4 4311/4885 |
| US-20140206618-A1 | Inhibitors of the Renal Outer Medullary Potassium Channel | KCNJ11, KCNJ1, KCNJ2 | CHRNA7 2135/4885CHRNB2 2627/4885CHRNB4 3036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.